• Tuberculosis and Respiratory Diseases
• /
• 제50권3호
• /
• pp.367-372
• /
• 2001

Bacillus Calmette-Guerin(BCG) has been widely used for the prophylaxis of superficial bladder tumor recurrence and for the treatment of bladder carcinoma in situ. More than 95% of patients who receive BCG instillation tolerate the treatment well and side reactions have been reported in less than 5% of patients. Most side effects are minor and self-limiting. However, a rare occurrence of severe systemic reactions have been reported. Among the severe systemic reactions, hypersensitivity pneumonitis should be considered in patients with pneumonic complications after BCG instillation in cases where the culture for mycobacteria is negative in the sputwn, brochoalveolar lavage and blood specimen. In addition, a fiberoptic bronchoscopy with transbronchial lung biopsy demonstrates a fibrosis of the alveolar septums, where there is and an increased lymphocyte count with out tuberculous inflammatory changes, the and CD4 : CD8 ratio is increased and no symptomatic response to antituberculosis chemotherapy is observed. Here we report a 68 years old man with interstitial pneumonitis following intravesical BCG instillation.

• Journal of Yeungnam Medical Science
• /
• 제40권4호
• /
• pp.430-434
• /
• 2023

Intravesical bacillus Calmette-Guérin (BCG) instillation is an adjuvant treatment for non-muscle-invasive urinary bladder cancer. Although most complications associated with BCG immunotherapy are mild and self-limiting, rare albeit serious complications have been reported. Only a few cases of BCG-related rhabdomyolysis have been reported. In this study, we present the case of a 72-year-old woman who developed severe weakness and hyperCKemia following intravesical BCG instillation. A muscle biopsy was performed, and a diagnosis of drug-induced myopathy was made.

• Tuberculosis and Respiratory Diseases
• /
• 제46권6호
• /
• pp.869-878
• /
• 1999

표재성 방광암의 치료는 경요도적 절제술 후 방광내 BCG 투여가 표준적인 치료로 알려져 있다. 방광내 BCG 투여 후 가장 흔한 부작용은 방광자극, 빈뇨감, 배뇨 곤란 등이며 항결핵제를 사용해야 할 정도의 전신적인 부작용은 5% 이하로 알려져 있다. 저자들은 표재성 방광암 환자에서 경요도적 절제술 후 방광내 BCG 주입치료 후 폐합병증이 발생한 2예를 경험하여 문헌고찰과 함께 보고하는 바이다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권9호
• /
• pp.4357-4361
• /
• 2012

Objective: The guidelines on indications for prophylactic use of Bacille Calmette-Gu$\acute{e}$rin (BCG) against non-muscle-invasive bladder cancer (NMIBC) have changed over the years. In order to assess the impact on outcome, the present retrospective comparison of BCG efficacy by time period with Japanese patients was conducted. Patients and Methods: A total of 146 cases of NMIBC treated with BCG since February 1985 were retrospectively evaluated. All patients received 80 mg of BCG (Tokyo 172 strain) six to eight times a week for prophylactic use. Comparison was made among three historical groups (Group A: 1980's, 39 cases; Group B: 1990's, 61 cases; Group C: 2000's, 46 cases). Results: In total, recurrence was seen in 55 of the 146 cases (37.7%), and progression in 14 (9.6%), 1 patient dying of cancer. These overall results were similar to those outlined in previous reports. However, the outcomes of this time-period-based analysis indicated a tendency for a shorter time to recurrence in patients after 2000, although a log-rank test showed no significance (P=0.229). Seven of the cases featuring progression (i.e., half of all such cases) were among the 46 Group C patients (15.2%). Excluding these progressive cases, there was no significant difference among the remaining 132 patients in the three groups. Conclusion: This study results revealed a tendency for a lower non-recurrence rate after 2000 in our series. This could stem from a number of factors, including changes in BCG indication criteria and the evolution of histopathological diagnostic criteria.

• Journal of Yeungnam Medical Science
• /
• 제4권2호
• /
• pp.113-120
• /
• 1987

백서에서 formalin의 방광점막하주사가 상피의 탈락을 일으키는지의 여부와 기타 방광벽에 나타나는 변화를 알아보기 위하여 건강한 Sprague-Dawley 수컷 흰쥐(체중 350gm 내외) 36마리를 3군으로 나누어 Nembutal 복강내 마취하에 방광을 노출한 다음 생리적 식염수, 10% formalin과 4% formalin을 각각 0.01ml씩 각군 동물의 방광점막하에 주사한 후 1일, 2일, 3일, 1주, 2주 그리고 4주째에 방광을 적출하여 방광벽에 나타나는 육안적, 병리조직학적 소견을 관찰하여 다음과 같은 결과를 얻었다. 1. 10% formalin 주사군에서는 제 1주부터 4% formalin 주사군과 생리적 식염수 주사군에서는 제 2주부터 방광결석 형성을 볼 수 있었다. 2. 10% formalin 주사군과 4% formalin 주사군에 있어서 조직학적 소견의 차이는 없었다. 3. Formalin 주사군에서는 점막궤양 또는 현저한 정막붕괴가 24시간째에 나타나고 점막재생은 제 2일부터 시작하여 제 3일에 현저하였고 제 1주에는 거의 정상적인 상피화를 보였다. 4. 상피하 부종, 혈판확장 및 염증반응은 24시간 째에 현저하였고, 상피하 부종은 제 1주까지, 혈판확장과 염증반응은 제4주까지 중등도로 지속되었다. 섬유아세포증식은 제2일부터 나타나 제4주까지 중등도로 지속되었다. 5. 본 실험중 동물이 죽거나 방광천공을 일으킨 예는 없었다. 이상의 결과로 미루어보아 formalin의 방광점막하 주사는 이로 인해 파괴되는 조직의 범위와 그 재생과의 관계가 보다 명백히 규명되면 재발성 표재성 방광암 환자의 선별적인 예의 치료에 응용해, 볼 가치가 있을 것으로 생각된다.